3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms, Castration-Resistant
1
Interventions
enzalutamide
5
Docetaxel
3
zimberelimab
1
sacituzumab govitecan
1
quemliclustat
1
olaparib
1
gedatolisib
1
fludrocortisone acetate
1
darolutamide
1
cabazitaxel
1
abiraterone
1
Prednisone
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms, Castration-Resistant
×
fludrocortisone acetate
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled